Capecitabine for squamous cell carcinoma reduction in solid organ transplant recipients

Immunosuppression associated with solid organ transplantation significantly increases the rate of nonmelanoma skin cancer (NMSC) development, in particular squamous cell carcinomas (SCCs). In certain cases, the rate at which these malignancies develop can be too rapid for traditional surgical or field treatments. In these cases, chemopreventative treatments should be considered to decrease the rate of NMSC development so that the remaining can be managed by more traditional treatments. Herein, we show that capecitabine can be used as a viable chemopreventative option for these difficult cases.